Medicine
Reblozyl 75 mg powder for injection
Reblozyl 75 mg powder for injection is a prescription medicine containing Luspatercept for subcutaneous use, marketed by Celgene, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to…
Key facts
- Active ingredient (INN)
- Luspatercept
- Brand
- Reblozyl
- Strength
- 75 mg
- Dosage form
- Powder for injection
- Route
- Subcutaneous
- Packs
- 1 vial
- Marketing authorisation holder
- Celgene
- Manufacturer
- Celgene
- Origin register
- US FDA, United States
- Storage
- Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B03XA06 Luspatercept
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 November 2019
- Identifiers
- RxCUI 2262906, 2262911, 2262913 +1DailyMed set ID 82f4d266-3f52-41eb-86ba-0abf3cf468e8NDC 59572-775Application BLA761136
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, glass | 59572-775-01 | Celgene | 8 November 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Luspatercept
Clinical summary
Luspatercept is an erythroid maturation agent indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions, among other approved uses. MedsAcross supplies Luspatercept for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LuspaterceptFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Reblozyl prescribing information (Celgene) · U.S. National Library of Medicine, DailyMed
- Reblozyl: European public assessment report (EPAR) · European Medicines Agency
Need Reblozyl 75 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.